2 completed, 2 recruiting, 1 terminated, 1 withdrawn. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 2, Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Gallbladder Carcinoma: new trials by email Literature Review of Gallbladder Carcinoma trials Research Report on Gallbladder Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide - Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 30 | 2026-03-02 | 2026-06-11 |
| Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases Cisplatin, Gemcitabine, Nab-paclitaxel - Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 12 | 2022-09-19 | 2026-08-03 |
| A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors Felmetatug Vedotin, Pembrolizumab - Ovarian Neoplasms, Peritoneal Neoplasms | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 250 | 2022-01-12 | 2026-01-09 |
| A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors ELI-002 2P - Minimal Residual Disease, KRAS G12D | Phase 1 | Completed | Elicio Therapeutics | 25 | 2021-10-04 | 2025-09-05 |
| A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer MEK 162, Gemcitabine, Oxaliplatin - Biliary Tract Carcinoma, Gallbladder Carcinoma | Phase 1 | Withdrawn | University Health Network, Toronto | 2015-06-01 | 2018-02-19 | |
| Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Leucovorin Calcium, Irinotecan Hydrochloride - Adenocarcinoma of Unknown Primary, Adult Cholangiocarcinoma | Phase 1 | Completed | University of Chicago | 50 | 2014-12-01 | 2023-05-31 |
Gallbladder Neoplasms (6) · Cholangiocarcinoma (5) · Carcinoma, Non-Small-Cell Lung (2) · Ovarian Neoplasms (2) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Carcinoma, Adenoid Cystic (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gastrointestinal Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasm, Residual (1) · Pancreatic Neoplasms (1)
Biliary Tract Diseases (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gallbladder Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Adenocarcinoma (5) · Biliary Tract Neoplasms (5) · Carcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Adnexal Diseases (2) · Bronchial Neoplasms (2)
Albumin-Bound Paclitaxel (2) · Gemcitabine (2) · Taxes (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · Cisplatin (1) · Cyclophosphamide (1) · Fluorouracil (1) · Irinotecan (1) · Leucovorin (1) · Oxaliplatin (1) · Platinum (1) · fludarabine (1) · pembrolizumab (1)
Beijing Biotech (1) · City of Hope Medical Center (1) · Elicio Therapeutics (1) · Seagen, a wholly owned subsidiary of Pfizer (1) · University Health Network, Toronto (1) · University of Chicago (1)
United States (4) · Canada (1) · China (1) · Germany (1) · Spain (1) · United Kingdom (1)
Daneng Li, MD (1) · Jennifer Knox, M.D. (1) · Manish Sharma (1) · Mustafa Raoof, MD (1)
PMID 38195752, PMID 39263892, PMID 40790272
2023 (1), P30CA014599 (1), P30CA033572 (1)